UNSPSC 51273605: Cocaine

This classification denotes a cns stimulant with the molecular formula C17H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I5Y540LHVR, chemically known as 8-azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1r-(exo,exo))- but generally known as cocaine, which bears US NIH Compound Identifier 5760. European Medicines Agency schedules Cocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13416MIG.

UNSPSC 51273605 Cocaine is a Commodity code that shows a fundamental mismatch between its nominal scope and actual state and local procurement activity. The code classifies a controlled substance; however, recent opportunities posted under this code concern naloxone (an opioid antagonist used to reverse overdose), generic pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs — none of which involve cocaine. The mismatch suggests either a tagging error in the state procurement system or a category designation that does not align with current buying patterns. State and local governments buying under this code appear to include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances supporting public health and pharmacy benefit programs.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023, with the date discrepancy appearing in the source record) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through an e-procurement portal, with quarterly deliveries required and contract award based on fixed-fee pricing. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, an exploratory market-intelligence solicitation without formal timelines or budget figures. The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with contract award effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. No awards, vendor names, or set-aside designations appear in the source material.